Table 3.
PSA screening and prostate cancer incidence among PWH and Controls
| Men With HIV (n=37, 819) | Men Without HIV (n=85,653) | p-value | |
|---|---|---|---|
| PSA testing ever, n (%) | 28,713 (76) | 71,510 (84) | <0.001 |
| UNADJUSTED MODELS | Incidence Rate Ratio (95% CI) | ||
| Longitudinal PSA testing in PWH | 0.92 (0.91–0.92) | <0.001 | |
| Prostate biopsy in PWH | 0.79 (0.75–0.84) | <0.001 | |
| Prostate cancer in PWH | 0.90 (0.83–0.97) | 0.008 | |
| ADJUSTED MODELS* | Incidence Rate Ratio (95% CI) | ||
| Longitudinal PSA testing in PWH | 0.87 (0.75–0.84) | <0.001 | |
| Prostate biopsy in PWH | 0.79 (0.74–0.83) | <0.001 | |
| Prostate cancer in PWH | 0.89 (0.82–0.96) | 0.0042 | |
| Prostate cancer in PWH, model including PSA testing density | 0.93 (0.86–1.01) | 0.08 | |
| Prostate cancer in PWH, biopsied patients only | 1.06 (0.98–1.15) | 0.15 | |
| PROSTATE CANCER CASES | Men With HIV (n=787) | Men Without HIV (n=2,379) | |
| Summary Stage, n (%) | |||
| Localized | 680 (86) | 2116 (89) | 0.14 |
| Regional | 46 (6) | 137 (6) | |
| Metastatic | 23 (3) | 46 (2) | |
| Missing | 38 (5) | 80 (3) | |
| Gleason Grade (Sum), n (%) | |||
| 6 or Less | 264 (34) | 908 (38) | 0.05 |
| 7 | 285 (36) | 858 (36) | |
| 8 or Higher | 139 (18) | 348 (15) | |
| Missing | 99 (13) | 265 (11) | |
Abbreviations: PSA=prostate-specific antigen; PWH=persons with HIV; CI=Confidence interval
*
Models adjusted for age, race/ethnicity and smoking status